| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Amílcar Falcão | Q42629937 |
| Ana Fortuna | Q43005774 | ||
| Adriana O. Santos | Q45896991 | ||
| Raquel Seiça | Q47503991 | ||
| António J. Ribeiro | Q51128469 | ||
| P2093 | author name string | F Veiga | |
| A R Pinho | |||
| C Estevens | |||
| P2860 | cites work | Effects of the multilayer structures on Exenatide release and bioactivity in microsphere/thermosensitive hydrogel system | Q90271786 |
| A liquid chromatography high-resolution mass spectrometry in vitro assay to assess metabolism at the injection site of subcutaneously administered therapeutic peptides | Q90444913 | ||
| Pharmacological Signatures of the Exenatide Nanoparticles Complex Against Myocardial Ischemia Reperfusion Injury | Q90757201 | ||
| A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond | Q26799389 | ||
| Advances in targeted proteomics and applications to biomedical research | Q28066912 | ||
| Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus | Q30249371 | ||
| Targeted proteomics analysis of protein degradation in plant signaling on an LTQ-Orbitrap mass spectrometer. | Q30317151 | ||
| Simultaneous determination of incretin hormones and their truncated forms from human plasma by immunoprecipitation and liquid chromatography-mass spectrometry | Q30320514 | ||
| Multiplexed MS/MS for improved data-independent acquisition | Q30651066 | ||
| Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments | Q30749426 | ||
| Use of proteomic patterns in serum to identify ovarian cancer | Q30819686 | ||
| Multiplexed, Scheduled, High-Resolution Parallel Reaction Monitoring on a Full Scan QqTOF Instrument with Integrated Data-Dependent and Targeted Mass Spectrometric Workflows | Q30996203 | ||
| Analysis and validation of proteomic data generated by tandem mass spectrometry | Q31131394 | ||
| One-step purification of a fusion protein of glucagon-like peptide-1 and human serum albumin expressed in pichia pastoris by an immunomagnetic separation technique | Q33305182 | ||
| Development and validation of a rapid high-performance liquid chromatography method for the quantification of exenatide. | Q33705580 | ||
| Targeted data extraction of the MS/MS spectra generated by data-independent acquisition: a new concept for consistent and accurate proteome analysis | Q34133645 | ||
| A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. | Q34343581 | ||
| Liquid Chromatography Mass Spectrometry-Based Proteomics: Biological and Technological Aspects | Q34983181 | ||
| Glucagon-like peptide-1 (GLP-1) analogs: recent advances, new possibilities, and therapeutic implications. | Q35087846 | ||
| Using data-independent, high-resolution mass spectrometry in protein biomarker research: perspectives and clinical applications | Q35518214 | ||
| Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials | Q35784245 | ||
| Mildly acidic conditions eliminate deamidation artifact during proteolysis: digestion with endoprotease Glu-C at pH 4.5. | Q35889468 | ||
| The impact of phospholipids and phospholipid removal on bioanalytical method performance | Q35895799 | ||
| A liquid chromatography-mass spectrometry assay for quantification of Exendin[9-39] in human plasma. | Q35898828 | ||
| Advancing the sensitivity of selected reaction monitoring-based targeted quantitative proteomics | Q36031629 | ||
| Synthetic small molecule GLP-1 secretagogues prepared by means of a three-component indole annulation strategy | Q36063472 | ||
| Comprehensive N-Glycan Profiling of Cetuximab Biosimilar Candidate by NP-HPLC and MALDI-MS. | Q36245448 | ||
| Evaluation of an [(18)F]AlF-NOTA Analog of Exendin-4 for Imaging of GLP-1 Receptor in Insulinoma | Q36383709 | ||
| Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 | ||
| Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy | Q37402786 | ||
| Mechanisms of inflammatory responses and development of insulin resistance: how are they interlinked? | Q37470376 | ||
| Incretin-based therapies for type 2 diabetes mellitus | Q37483473 | ||
| Interleukin-1 receptor antagonist: a new therapy for type 2 diabetes mellitus | Q37978230 | ||
| GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus | Q38040314 | ||
| Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1. | Q38066566 | ||
| Liquid chromatographic methods for the quantification of catecholamines and their metabolites in several biological samples--a review | Q38087673 | ||
| Protein-based matrix interferences in ligand-binding assays. | Q38211931 | ||
| Sample preparation strategies for targeted proteomics via proteotypic peptides in human blood using liquid chromatography tandem mass spectrometry | Q38270732 | ||
| Potential side effects to GLP-1 agonists: understanding their safety and tolerability | Q38286444 | ||
| Recent advances in targeted proteomics for clinical applications | Q38287678 | ||
| Exenatide Extended-Release: An Updated Review of Its Use in Type 2 Diabetes Mellitus | Q38526870 | ||
| The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide | Q38599958 | ||
| In Vivo Target Validation Using Biological Molecules in Drug Development | Q38629068 | ||
| Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review | Q38634679 | ||
| Insulin glargine and its two active metabolites: A sensitive (16pM) and robust simultaneous hybrid assay coupling immunoaffinity purification with LC-MS/MS to support biosimilar clinical studies | Q38636682 | ||
| Bioanalytical challenge: A review of environmental and pharmaceuticals contaminants in human milk. | Q38884195 | ||
| Sample clean-up strategies for ESI mass spectrometry applications in bottom-up proteomics: Trends from 2012 to 2016. | Q38921700 | ||
| Pharmacokinetic/pharmacodynamic studies on exenatide in diabetic rats | Q39276306 | ||
| Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassays | Q41078498 | ||
| Successful Colistin Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infection Using a Rapid Method for Determination of Colistin in Plasma: Usefulness of Therapeutic Drug Monitoring | Q41117701 | ||
| Development of a high-throughput UHPLC-MS/MS (SRM) method for the quantitation of endogenous glucagon from human plasma | Q41656530 | ||
| In vivo evaluation of an oral self-emulsifying drug delivery system (SEDDS) for exenatide | Q88158821 | ||
| Current Mass Spectrometric Tools for the Bioanalyses of Therapeutic Monoclonal Antibodies and Antibody-Drug Conjugates | Q88334299 | ||
| The use of low molecular weight protamine to enhance oral absorption of exenatide | Q88815505 | ||
| Recent developments and applications of different sorbents for SPE and SPME from biological samples | Q88936427 | ||
| Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogs | Q43245526 | ||
| Pharmacokinetics and efficacy of a biweekly dosage formulation of exenatide in Zucker diabetic fatty (ZDF) rats | Q43276080 | ||
| A long-acting formulation of a polypeptide drug exenatide in treatment of diabetes using an injectable block copolymer hydrogel | Q43735089 | ||
| Selectivity of LC-MS/MS analysis: implication for proteomics experiments. | Q43864979 | ||
| Recombination and functional studies of a dual-action peptide for diabetes | Q44227850 | ||
| Application of DBS for Quantitative Assessment of the Peptide Exendin-4; Comparison of Plasma and DBS Method by UHPLC–MS/MS | Q45400105 | ||
| Multilayer nanoparticles for sustained delivery of exenatide to treat type 2 diabetes mellitus | Q45691518 | ||
| Large-molecule quantification: sensitivity and selectivity head-to-head comparison of triple quadrupole with Q-TOF. | Q46069949 | ||
| Active phytochemicals of Pueraria tuberosa for DPP-IV inhibition: in silico and experimental approach. | Q46339499 | ||
| Effect of water on exenatide acylation in poly(lactide-co-glycolide) microspheres | Q46562749 | ||
| Stability of exenatide in poly(D,L-lactide-co-glycolide) solutions: a simplified investigation on the peptide degradation by the polymer | Q47227494 | ||
| Purification, identification and molecular mechanism of two dipeptidyl peptidase IV (DPP-IV) inhibitory peptides from Antarctic krill (Euphausia superba) protein hydrolysate | Q47670208 | ||
| Minimizing target interference in PK immunoassays: new approaches for low-pH-sample treatment | Q47884443 | ||
| Dipeptidyl peptidase-IV inhibitory peptides generated by tryptic hydrolysis of a whey protein concentrate rich in β-lactoglobulin. | Q50887910 | ||
| In vivo imaging of the glucagonlike peptide 1 receptor in the pancreas with 68Ga-labeled DO3A-exendin-4. | Q50912475 | ||
| Multiplexed Quantification of Proglucagon-Derived Peptides by Immunoaffinity Enrichment and Tandem Mass Spectrometry after a Meal Tolerance Test. | Q50928547 | ||
| DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. | Q51379684 | ||
| Tf ligand-receptor-mediated exenatide-Zn2+ complex oral-delivery system for penetration enhancement of exenatide. | Q52331353 | ||
| A review of analytical procedures for the simultaneous determination of medically important veterinary antibiotics in environmental water: Sample preparation, liquid chromatography, and mass spectrometry. | Q52591543 | ||
| Mechanistic studies for monodisperse exenatide-loaded PLGA microspheres prepared by different methods based on SPG membrane emulsification. | Q53520319 | ||
| Purification, identification and structural modelling of DPP-IV inhibiting peptides from barbel protein hydrolysate. | Q53779614 | ||
| Type 2 diabetes mellitus | Q58447602 | ||
| Comparison of triple quadrupole and high-resolution TOF-MS for quantification of peptides | Q61971658 | ||
| Enhancing Stability of Exenatide-Containing Pressurized Metered-Dose Inhaler Via Reverse Microemulsion System. | Q64892504 | ||
| Evidence for presence of IgG4 anti-immunoglobulin autoantibodies in all human beings | Q73814611 | ||
| Pathology: Cause and effect | Q74440795 | ||
| Impact of GHBP interference on estimates of GH and GH pharmacokinetics | Q78596759 | ||
| Human heterophilic antibodies display specificity for murine IgG subclasses | Q81633049 | ||
| Bioanalytical strategies for developing highly sensitive liquid chromatography/tandem mass spectrometry based methods for the peptide GLP-1 agonists in support of discovery PK/PD studies | Q82045686 | ||
| Application of novel peptide (Pp1) improving the half-life of exendin-4 in vivo | Q83445268 | ||
| Combination of ELISA and dried blood spot technique for the quantification of large molecules using exenatide as a model | Q83940517 | ||
| Peptide complex containing GLP-1 exhibited long-acting properties in the treatment of type 2 diabetes | Q84273969 | ||
| Combined use of immunoassay and two-dimensional liquid chromatography mass spectrometry for the detection and identification of metabolites from biotherapeutic pharmacokinetic samples | Q84402539 | ||
| Intravitreal Injection of Exendin-4 Analogue Protects Retinal Cells in Early Diabetic Rats | Q84676969 | ||
| Development of a fast method for direct analysis of intact synthetic insulins in human plasma: the large peptide challenge | Q85750599 | ||
| Preparation of uniform-sized exenatide-loaded PLGA microspheres as long-effective release system with high encapsulation efficiency and bio-stability | Q86055776 | ||
| In vitro and in vivo evaluation of a once-weekly formulation of an antidiabetic peptide drug exenatide in an injectable thermogel | Q86506211 | ||
| Development and validation of a multi-residue screening method for veterinary drugs, their metabolites and pesticides in meat using liquid chromatography-tandem mass spectrometry | Q86621984 | ||
| Acylation of exenatide by glycolic acid and its anti-diabetic activities in db/db mice | Q87320247 | ||
| P433 | issue | 3 | |
| P921 | main subject | liquid chromatography–mass spectrometry | Q873864 |
| P304 | page(s) | 143-155 | |
| P577 | publication date | 2019-02-26 | |
| P1433 | published in | Journal of Pharmaceutical Analysis | Q27725801 |
| P1476 | title | Comparison of ELISA and HPLC-MS methods for the determination of exenatide in biological and biotechnology-based formulation matrices | |
| P478 | volume | 9 |
Search more.